March 24, 2026
Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody
Sanofi has signed an exclusive global licence agreement with Kali Therapeutics for KT501, a new tri-specific antibody for B cell-mediated autoimmune diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







